Tag: enzalutamide
1. Enzalutamide along with androgen-deprivation therapy was shown to significantly increase median overall survival among men with non-metastatic, castration-resistant prostate cancer.
2. Adverse events for enzalutamide and androgen-deprivation therapy were shown to be consistent with the established safety profile of enzalutamide.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Enzalutamide is an approved therapy for...
1. Enzalutamide along with androgen-deprivation therapy was shown to significantly increase median overall survival among men with non-metastatic, castration-resistant prostate cancer.
2. Adverse events for enzalutamide and androgen-deprivation therapy were shown to be consistent with the established safety profile of enzalutamide.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Enzalutamide is an approved...
1. Prostate cancer patients with a rapidly risking prostate-specific antigen (PSA) despite chemical or physical castration had lower rates of metastasis when treated with enzalutamide compared to those in a placebo group.
2. No difference in overall survival was observed between the treatment and placebo groups at a median follow-up...